In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Rodriguez, Carlos A ^a   Agudelo, Maria ^a   Zuluaga, Andres F ^a   Vesga, Omar ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; GENERIC DRUG; OXACILLIN; PROSTAFILINA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOSTASIS; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TREATMENT FAILURE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MOUSE STRAIN; NEUTROPENIA; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUGS, GENERIC; FEMALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OXACILLIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 77952961574     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-153     Document Type: Article

References (26)

1. Enright MC. The evolution of a resistant pathogen--the case of MRSA. Curr Opin Pharmacol 2003, 3:474-479. 10.1016/S1471-4892(03)00109-7, 14559091.
2. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 2003, 25:2875-2890. 10.1016/S0149-2918(03)80340-5, 14693311.
3. Food and Drug Administration (FDA) Guidance for industry. Statistical Approach to Establishing Bioequivalence. 2009, Food and Drug Administration (FDA).
4. United States Pharmacopeial Convention (USP) United States Pharmacopeia and National Formulary 1999, Rockville, MD: USP, United States Pharmacopeial Convention (USP).
5. Rodriguez CA, Zuluaga AF, Salazar BE, Agudelo M, Vesga O. Experimental comparison of 11 generic products of oxacillin with the original compound in terms of concentration of active principle, in vitro activity, and in vivo efficacy, using the neutropenic murine thigh infection model [Abstract A-1305]. Abstracts of the 44th ICAAC 2004, 28-29.
6. Zuluaga AF, Agudelo M, Rodriguez CA, Vesga O. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics. BMC Clin Pharmacol 2009, 9:1. 10.1186/1472-6904-9-1, 2640365, 19149891.
7. Bennett JV, Brodie JL, Benner EJ, Kirby WM. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol 1966, 14:170-177. 546645, 4959982.
8. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility test for bacteria that grow, approved standard M7-A6. 2003, Clinical and Laboratory Standards Institute (CLSI).
9. Zuluaga AF, Salazar BE, Rodriguez CA, Zapata AX, Agudelo M, Vesga O. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect Dis 2006, 6:55. 10.1186/1471-2334-6-55, 1434751, 16545113.
10. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10. 10.1086/516284, 9455502.
11. Motulsky H, Christopoulos A. Fitting models to biological data using linear and nonlinear regression 2003, San Diego: Oxford University Press.
12. Christopoulos A, Grant MK, Ayoubzadeh N, Kim ON, Sauerberg P, Jeppesen L, El-Fakahany EE. Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther 2001, 298:1260-1268.
13. Roy J. Pharmaceutical impurities--a mini-review. AAPS PharmSciTech 2002, 3:E6. 10.1208/pt030206, 12916943.
14. Rodriguez CA, Agudelo M, Catano JC, Zuluaga AF, Vesga O. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia. J Infect 2009, 59:277-280. 10.1016/j.jinf.2009.08.005, 19698745.
15. Senn S. In the blood: proposed new requirements for registering generic drugs. Lancet 1998, 352:85-86. 10.1016/S0140-6736(98)85007-1, 9672271.
16. Welage LS, Kirking DM, Ascione FJ, Gaither CA. Understanding the scientific issues embedded in the generic drug approval process. J Am Pharm Assoc (Wash) 2001, 41:856-867.
17. World Health Organization (WHO) Marketing Authorization of Pharmaceutical Products with Special Reference to Multisource (Generics) Products: A Manual for Drug Regulatory Authorities. 1998, WHO, Geneva, World Health Organization (WHO).
18. Eagle H, Musselman AD. The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms. J Exp Med 1948, 88:99-131. 10.1084/jem.88.1.99, 2135799, 18871882.
19. Vesga O. Generics and Generics [Abstract 1338]. Abstracts of the 45th ICAAC 2005, 508.
20. Cole M, Kenig MD, Hewitt VA. Metabolism of penicillins to penicilloic acids and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption. Antimicrob Agents Chemother 1973, 3:463-468. 444435, 4364176.
21. Mastoraki E, Michalopoulos A, Kriaras I, Mouchtouri E, Falagas ME, Karatza D, Geroulanos S. Incidence of postoperative infections in patients undergoing coronary artery bypass grafting surgery receiving antimicrobial prophylaxis with original and generic cefuroxime. J Infect 2008, 56:35-39. 10.1016/j.jinf.2008.02.004, 17983660.
22. Vasudevan TK, Rao VSR. Conformational studies of phenyl and isoxazolyl penicillins. Current Science 1984, 51:402-406.
23. Rao VS, Vasudevan TK. Conformation and activity of beta-lactam antibiotics. CRC Crit Rev Biochem 1983, 14:173-206. 10.3109/10409238309102793, 6354584.
24. Stratton CW. Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 2003, 9:10-16. 2873758, 12533275.
25. Rodriguez CA, Agudelo M, Graciano N, Zuluaga AF, Vesga O. Generic vancomycin enriches resistant subpopulations of S. aureus after treatment in the neutropenic mouse thigh infection model [Abstract A-648]. Abstracts of the 46th ICAAC 2006, 17.
26. Zuluaga AF, Agudelo M, Cardeño JJ, Rodriguez CA, Vesga O. Determination of therapeutic equivalence of generic products of gentamicin in the neutropenic mouse thigh infection model. PLoS ONE 2010, 5(5):e10744. 10.1371/journal.pone.0010744, 2873963, 20505762.